60 DEGREES PHARMACEUTICALS, INC. 8-K — AI Bull & Bear Analysis

The 8-K filing clarifies 60 Degrees Pharmaceuticals' intent to leverage the FDA's incentive structure to accelerate its corporate valuation. While the pursuit of a Priority Review Voucher offers a lucrative path to non-dilutive funding and faster market entry, it ties the company's near-term success to a specific clinical window ending in early 2028. The overall impact is a shift in investor perception from a standard biotech play to a high-stakes regulatory bet, where the primary value driver is as much about the voucher's tradable value as it is about the therapeutic efficacy of tafenoquine.